Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis

) and relapsing-remitting MS (RR-MS) patients. A total of 100 patients will receive Tovaxin, while 50 will receive placebo. The study is designed as a two-arm, 52-week, parallel-group study, whereby patients will be given five subcutaneous injections at 0, 4, 8, 12 and 24 weeks. The analyses will be performed at the end of the 52-week study to assess the safety and efficacy of Tovaxin. The primary efficacy variable is the cumulative number of gadolinium-enhancing lesions on T1-weighted MRI scans summed over the Week 28, 36, 44, and 52 MRIs. The secondary efficacy variables are the cumulative number of new gadolinium-enhancing lesions at Weeks 28-52, the change in T2-weighted lesion volume, and the annualized relapse rate. As of March 19, 2007, Opexa reported that more than 110 patients have been enrolled in the TERMS clinical trial and the Company expects enrollment to be complete by mid 2007.

All patients who complete the trial will be eligible to participate in an optional one-year extension study, in which they will receive Tovaxin under an open-label protocol. The open-label study is being planned under a different protocol that will be submitted to the FDA.

The TERMS study is being conducted at 36 U.S. sites to evaluate the safety and effectiveness of Tovaxin It is registered on the U.S. National Institutes of Health-sponsored website, www.clinicaltrials.gov, where pharmaceutical companies are required to register trials for medicines that will treat serious or life-threatening diseases or conditions. For more information, visit the TERMS website at www.tovaxin.com.

About T-cell Vaccination

For a T-cell vaccine to be effective, it should be able to induce T-cell cytotoxic and/or regulatory immune responses against the pathogenic T-cells. Studies of T-cell vaccine have indicated that T-cell vaccination with peripheral blood-derived autologous myelin-peptide selected T-cells in multiple sclerosis patients resulted in the in vivo induct
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)...  RESMED INC. (NYSE: RMD ) today announced ... ended June 30, 2014 results on Thursday, July 31, 2014, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
(Date:7/10/2014)... July 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... it has completed the sale to Galderma of all ... or held by Valeant for $1.4 billion in cash, ... which recently completed its acquisition of Galderma. ... our products to a company that is firmly committed ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
(Date:7/11/2014)... Virginia (PRWEB) July 11, 2014 ASHBURN PSYCHOLOGICAL ... took effect, which allows individuals with an intellectual disability or ... of their licenses and ID cards to alert law enforcement ... a condition. The idea was inspired by a central ... in protecting her 9 year old autistic son, JP. ...
(Date:7/10/2014)... More than 200 experts on aggression, who research ... will attend the 21st World Meeting of the ... the Loews Atlanta Hotel, July 15-19. , Georgia ... which is held every other year on alternating continents. ... scholars from more than 20 different countries, which will ...
(Date:7/10/2014)... New York, US (PRWEB) July 10, 2014 ... . , Merrill DataSite recently streamed the live webinar ... featuring a discussion from a group of several M&A ... are seeing in the broader energy transaction marketplace. These ... hot and how the deal market in this sector ...
(Date:7/10/2014)... 10, 2014 A Forever Recovery ... gets clients off to a great start and gives ... in, has launched a new Eating Disorders section of ... section highlights:, , Different types of ... of Mental Disorders (DSM-IV), including anorexia nervosa, bulimia nervosa, ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Nature, not nurture, may play ... chimpanzees, a new study finds. "As is the ... cognitive [thinking] abilities in chimpanzees," William Hopkins of the ... a news release from the journal Current Biology ... the evolution of intelligence in humans, Hopkins, team said. ...
Breaking Medicine News(10 mins):Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 2Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 3Health News:Georgia State Hosts National Conference On Aggression 2Health News:Georgia State Hosts National Conference On Aggression 3Health News:Georgia State Hosts National Conference On Aggression 4Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Like Humans, Chimps' Smarts May Rely on Genes 2
... research reports published in the new issue of Archives ... vascular birthmarks with treatment procedures like laser therapy and ... internal, or form an external birthmark and can be ... ,The researchers had presented the current treatment approaches for ...
... genetic disorder characterized by distorted, sickle shaped red blood cells. ... damage to the kidneys, spleen, and liver. The sickle cell ... is about 1 in 500., ,Despite much clinical work, ... can be relieved, and the frequency and duration of the ...
... Researchers at the University of California in San Francisco ... fruit and vegetables can reduce the risk of pancreatic ... most strongly associated with increased // protection were onions, ... potatoes, corn and yellow squash), dark leafy vegetables and ...
... medical journal The Lancet had published a research ... health workers., ,Poor health-worker performance is a ... In the current issue of The Lancet researchers ... for how high-quality health-worker performance can be achieved., ...
... Molecular Immunologist and his team has found a new virus ... inflammation and autoimmune diseases. The new delivery system acts as ... virus containing the required genes are transferred into the T ... the immune cells they get attracted towards the cancer cell ...
... have been reported to experience 25% less muscle and joint ... active. Furthermore, the study has also revealed that people who ... experience less pain than non-runners even though they are more ... study involved comparison of the level of pain in a ...
Cached Medicine News:Health News:Hydroxyurea Treatment For Children With Sickle Cell Disease 2
... helps you deliver unmatched performance through patient-focused ... the most complete anesthesia solution developed, putting ... - at your fingertips., ,The Aisys ... legacy of anesthesia delivery and patient monitoring ...
... Premilene Mesh LP Self-Forming Plug is combining ... This results in a very soft hernia plug ... to standard Plugs less foreign body material is ... the hernia size and shape allows for a ...
... Celsius Control System provides physicians,with ... safely,and rapidly lower patient body ... temperature and,rewarm patients to normothermic ... consists of an endovascular,catheter, console ...
... Fiberoptics Gemini surgical headlight is perfectly balanced ... durable and ultra-low-profile and illuminates brilliantly while ... annoying "rams effect." The fully adjustable headband, ... to sit low on the brow, directing ...
Medicine Products: